News from hospira A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 25, 2014, 06:06 ET El biosimilar Retacrit™ demuestra ser efectivo en la anemia inducida por quimioterapia

Hospira (NYSE: HSP), el proveedor líder mundial de fármacos inyectables y tecnologías de inyección, ha anunciado hoy que los resultados del estudio...


Jul 24, 2014, 09:31 ET La spécialité biosimilaire Retacrit™ efficace pour traiter l'anémie chimio-induite - Nouvelle publication de résultats de l'étude ORHEO dans la revue BMC Cancer

Hospira (NYSE : HSP), premier fournisseur mondial de médicaments injectables et de technologies de perfusion, a annoncé aujourd'hui la publication...


Jul 24, 2014, 03:37 ET Biosimilar Retacrit™ wirksam bei chemotherapeutisch induzierter Anämie - Neue Veröffentlichung von ORHEO-Studienergebnissen in BMC Cancer

Hospira (NYSE: HSP), der weltweit führende Anbieter von injizierbaren Arzneistoffen und Infusionstechnologien, gab heute bekannt, dass die Ergebnisse ...


Jun 17, 2014, 04:26 ET Hospira partilha resultados de ensaios randomizados que mostram que o anticorpo monoclonal biossimilar, Inflectra™, demonstra reduções comparáveis na atividade de doença relativamente ao Remicade® no período de um ano

Hospira (NYSE: HSP), o principal fornecedor a nível mundial de medicamentos injetáveis e tecnologias de infusão, apresentou, esta semana, dados que...


Sep 10, 2013, 05:50 ET Inflectra™ (infliximab) de Hospira el primer anticuerpo monoclonal biosimilar aprobado en Europa

Hospira (NYSE: HSP), principal proveedor mundial de fármacos inyectables y tecnologías de infusión, ha anunciado hoy que la Comisión Europea (CE)...


Sep 10, 2013, 05:48 ET Hospira's Inflectra™ (Infliximab) ist der erste biosimilare, monoklonale Antikörper, der in Europa zugelassen wird

Hospira (NYSE: HSP), weltweit führender Anbieter von injizierbaren Medikamenten und Infusionstechnik, gab heute die Zulassung von Inflectra™...


Sep 10, 2013, 05:44 ET Inflectra™ (infliximab) de la société Hospira représente le premier traitement biosimilaire par anticorps monoclonal à être approuvé en Europe

Hospira (NYSE : HSP), principal fournisseur mondial de médicaments injectables et de technologies de perfusion, a annoncé aujourd'hui que la...


Sep 10, 2013, 05:32 ET Hospira's Inflectra™ (infliximab) the first biosimilar monoclonal antibody to be approved in Europe

Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC)...


Jun 29, 2011, 05:26 ET Hospira Applauds North Carolina's New Legislation Aimed at Reducing Healthcare-Associated Infections

Hospira (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced its support for North...


May 23, 2011, 03:43 ET DSS and Hospira Win Veterans Affairs Industry Innovation Award for TheraDoc™ Clinical Surveillance System

Hospira (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced that Hospira and DSS, Inc., are ...


Apr 07, 2011, 12:37 ET Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance

As part of World Health Day 2011, the World Health Organization (WHO) is calling on policy makers, providers, the public and the healthcare industry...


Apr 01, 2011, 03:30 ET Hospira Launches Enhanced TheraDoc™ Clinical Surveillance System to Support Patient Safety and Help Improve Care

Hospira (NYSE:HSP), a leading provider of clinical information and medication delivery technologies, today announced the launch of its enhanced...


Oct 04, 2010, 10:19 ET Hospira Benoemt Svend Andersen om Europa, het Midden-Oosten en Afrika te Leiden

Hospira (NYSE: HSP), een wereldwijd bedrijf op het vlak van farmaceutische en medicatieleveringen, kwam vandaag met het nieuws dat Svend Andersen...


Oct 04, 2010, 10:12 ET Hospira nomina Svend Andersen alla guida di Europa, Medio Oriente e Africa

Hospira (NYSE: HSP), una società mondiale per la preparazione di farmaci e prodotti farmaceutici specialistici, ha annunciate oggi che Svend Andersen ...


Oct 04, 2010, 09:22 ET Hospira Navn Svend Andersen i ledelse av Europa, Midt-Østen og Afrika

Hospira (NYSE: HSP), et globalt spesialitet leverandør firma for farmasøytiske og medisinske produkter - kunngjorde idag at Svend Andersen har fått...


Oct 04, 2010, 06:00 ET Hospira udnævner Svend Andersen til chef for Europa, Mellemøsten og Afrika

Hospira (NYSE: HSP), der er en global leveringsvirksomhed med speciale indenfor medicinalindustrien og lægemiddelbranchen, offentliggjorte i dag at...


Oct 04, 2010, 05:08 ET Hospira nimittää Svend Andersenin johtamaan Eurooppaa, Lähi-itää ja Afrikkaa

Hospira (NYSE: HSP), maailmanlaajuinen lääketuotteisiin ja lääkintään erikoistunut yritys, ilmoitti tänään nimittäneensä Svend Andersenin tehtäviin...